Day 1 - Monday, 28 September 2020
Meeting category
Date(s)
28 Sep 2020 - 30 Sep 2020
Organizer
Titanium Level Support
Sponsor logos
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Related Enduring Materials
Enduring Materials
Preliminary Program
Opening - 10:00
10:00 EDT
Opening Remarks
Session 1: COVID-19 Session - 10:10
Mohammed Lamorde, FRCP, PhD
10:10 EDT
Emerging infections and Biosecurity
Infectious Diseases Institute, Makerere University College Of Health Sciences, Uganda, Africa
10:30 EDT
Clinical treatment of COVID-19
10:50 EDT
Role of Pharmacology of selection COVID candidates
11:10 EDT
FDA perspective on COVID-19
11:30 EDT
Faculty Discussion
Session 2: Abstracts Session - 12:30
12:30 EDT
Oral Abstract Presentation session
Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC #01
Jenna Yager, University of Colorado, USA
Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda #02
Letisha Najjemba, Infectious Disease Institute, Uganda
Time Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF Switch #03
Kristina Brooks, University of Colorado, USA
13:00 EDT
Live Q&A with Abstract Presenters
13:15 EDT
Oral Poster Presentations
TFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells #04
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
Mechanistic Modelling for the Quantitative Evaluation #05
Fazila Bunglawala, University of Liverpool, UK
Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design #06
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure #07
Micol Ferrara, Ospedale Amedeo Di Savoia, Italy
13:35 EDT
Live Q&A with Abstract Presenters
13:45 EDT
End of first day
DAY 2 - Tuesday, 29 September 2020
Session 3: Management of New Antivirals - 10:00
Marta Boffito, MD, PhD, FRCP, MBA
10:00 EDT
Pharmacology of bNABs
10:20 EDT
Clinical Pharmacology Long Acting ARVs
Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College London; United Kingdom
10:40 EDT
Development of Novel Formulations/Devices
11:00 EDT
Faculty Discussion
Session 4: Abstracts Session - 12:00
12:00 EDT
Oral Abstract Presentations - Population PK
Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants #08
Jincheng Yang, University of California San Diego, USA
In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models #09
Nicolas Cottura, University of Liverpool, UK
12:30 EDT
Live Q&A with Abstract Presenters
12:25 EDT
Oral Poster Presentations
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel Pbpk Models #10
-
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir #11
-
Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants #12
Teodora Pene Dumitrescu, Glaxosmithkline, USA
Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine #13
Parul Patel, ViiV Healthcare, USA
Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection #14
Katy Moore, ViiV Healthcare, USA
Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of JNJ-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers #15
Mina Pastagia, Janssen Biopharma, USA
Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV) #16
Thomas Kakuda, Janssen Biopharma, USA
Effect of Multiple-Dose Itraconazole on the Pharmacokinetics of Single-Dose JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Volunteers #17
Joris Vandenbossche, Janssen Biopharma, USA
13:00 EDT
Live Q&A with Abstract Presenters
13:15 EDT
End of second day
Online Networking Opportunities & E-Poster Viewing
DAY 3 - Wednesday, 30 September 2020
Session 5: Topic for Discussion - 10:00
10:00 EDT
Perspectives on the Use of Endogenous Biomarkers to Assess Transporter Mediated Drug-Drug Interactions (DDIs)
10:25 EDT
Role of herbal in DDIs
10:50 EDT
Faculty discussion
11:05 EDT
Virtual Coffee Break | Meet Your Colleagues
Session 6: Abstracts Session - 11:35
11:35 EDT
Oral Abstract Presentations - Special Populations - Pediatrics
Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age #18
Mina Nikanjam, University of California San Diego, USA
A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV #19
Vera Bukkems, Radboudumc, Netherlands
Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets #20
Rajendra Singh, Glaxosmithkline, USA
12:05 EDT
Live Q&A with Abstract Presenters
12:20 EDT
Oral Poster Presentations - Special Populations
Ledipasvir PK-PD (Pharmacokinetics - Pharmacodynamics): Relationship between drug exposure and sustained virologic response rates in a cohort of patientsRelationship Between Drug Exposure and Sustained Virologic Response Rates in a Cohort of Patients #21
Omar Elsherif, Queen Elizabeth Hospital Birmingham, UK
Exploring the Role of Age in Transporter-Related Drug-Drug Interactions #22
Hannah Kinvig, University of Liverpool, UK
Genetic Associations With Weight Gain Among South Africans Who Initiated Dolutegravir- and Tenofovir-Containing Regimens in the ADVANCE Study #23
Zinhle Cindi, University of Cape Town, South Africa
Rifabutin Pharmacokinetics and Safety Among TB/HIV Coinfected Young Children Receiving Lopinavir #24
Holly Rawizza, Brigham and Women's Hospital, USA
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers: A Preliminary #25
Jomy George, National Institutes of Health, USA
12:45 EDT
Live Q&A with Abstract Presenters
12:55 EDT
Closure - Best of Abstracts Awards
13:00 EDT
End of the Virtual Workshop
Overview
Committees
Support
Endorsers
Language
Related Programs
